WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq: INCY) anunció hoy nuevos resultados de su cartera oncológica en permanente desarrollo, incluida una actualización de los resultados de su inhibidor de KRAS G12D (INCB161734) en adenocarcinoma ductal pancreático (PDAC) y cáncer colorrectal (CRC) avanzado o metastásico, y su anticuerpo biespecífico contra TGFβR2×PD-1 (INCA338901) en cáncer colorrectal con estabilidad de microsatélites (MSS CRC). El comunicado en el idioma original es la versi
Author: sHq_LoGiNz
LONDON–(BUSINESS WIRE)– 26-October-2026 Issue: Coventry Building Society, CB Series 5 XS2498152920 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 01-October-2026 Date To: 02-November-2026 Record Date: 30-October-2026 Value Date: 02-November-2026 Benchmark Rate: 3.7384% Margin: 0.53% Total Rate: 4.2684% Floor: 0% Number of Days: 32 Day Count: Actual / 365 (Fixed) Interest Frequency: Monthly Total Amou
IRVINE, California, e AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., leader nell’oncologia di precisione per il tumore al seno, di recente ha illustrato una ricerca che presenta l’approccio sperimentale alla patologia digitale dell’azienda, basato sull’IA, per la firma delle recidive MammaPrint ® a 70 geni in occasione del Congresso mondiale 2026 della European Society for Medical Oncology (ESMO) a Madrid. La presentazione orale, a cura della co-fondatrice e responsabile della ricerca Laura van ‘t
LONDON–(BUSINESS WIRE)– 26-October-2026 Issue: Coventry Building Society, CB Series 4 XS2498152680 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 01-October-2026 Date To: 02-November-2026 Record Date: 30-October-2026 Value Date: 02-November-2026 Benchmark Rate: 3.7384% Margin: 0.53% Total Rate: 4.2684% Floor: 0% Number of Days: 32 Day Count: Actual / 365 (Fixed) Interest Frequency: Monthly Denominati
MÜNCHEN & LOS ANGELES–(BUSINESS WIRE)–Voor de eerste keer in de geschiedenis van de Olympische en Paralympische Spelen zal een wedstrijdstadion de naam van Allianz dragen. De Allianz Beach Arena in Long Beach, Californië, voor de Olympische en Paralympische Spelen van Los Angeles 2028 wordt het nieuwste lid van de Allianz Family of Stadiums. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst i
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. mAPMN/S is also known as metastatic hormone-sensitive prostate cancer
SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life, a pioneer in mechanistic artificial intelligence for drug discovery and development, today announced its participation in an initiative funded by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS) program. The initiative aims to revolutionize how living cells are preserved, stored, and transported, addressing one of the most significant barriers to scaling advanced cell therapies. Led by DesiCorp, t
هيوستن وسان فرانسيسكو–(BUSINESS WIRE)–وقّعت شركة Africa Critical Minerals Corporation (ACMC) وشركة Scepter, Inc. مذكرة تفاهم لاستخدام تقنيات الذكاء الاصطناعي التي تطورها Scepter لتقييم مشروعات المعادن الحيوية في أفريقيا، لصالح منصة التطوير التابعة لشركة ACMC.تعمل شركة ACMC على بناء محفظة من مشروعات المعادن الحيوية بالتعاون مع شركاء محليين في أفريقيا. كما تعمل الشركة على استحداث الفرص وتأمين الحقوق والاستثمار، إلى جانب استقطاب الشركاء الفنيين وشركاء التطوير والتمويل اللازمين لدفع كل مشروع قدمً
GRENOBLE, France–(BUSINESS WIRE)–Regulatory News: Données non auditées · Visioconférence le 27 octobre 2026 à 15h30 (CET) MEMSCAP (Euronext Paris : MEMS), fournisseur leader de solutions de capteurs de pression de haute précision et de forte stabilité pour les marchés de l’aéronautique et du médical, utilisant la technologie des MEMS (Micro Electro Mechanical Systems), annonce aujourd’hui son chiffre d’affaires et ses résultats consolidés non audités du troisième trimestre 2026, clos le 30 se
GRENOBLE, France–(BUSINESS WIRE)–Regulatory News: Unaudited figures · Video conference: Oct. 27, 3:30 p.m. CET MEMSCAP (Euronext Paris: MEMS), a leading provider of high-precision, high-stability pressure sensor solutions for the aerospace and medical markets based on MEMS (Micro Electro Mechanical Systems) technology, today announces its unaudited consolidated revenue and results for the third quarter of 2026, ended September 30, 2026, and for the first nine months of the fiscal year. Q3 202